Our API manufacturing facility “Macsen Drugs”, which is WHO-GMP certified and US-FDA registered, has obtained GMP certification from the TGA Australia.
Macsen Drugs receives EU Written Confirmations for 7 APIs
Prussian Blue is a medically approved antidote used to treat radioactive poisoning caused by isotopes such as cesium-137 and thallium. This blog explores its mechanism in cesium and thallium poisoning, dosing protocols for different age groups, safety considerations, and recent developments in radiological emergency preparedness.
Macsen Labs marks a key milestone in energy storage with the successful synthesis of high-performance Prussian White for advanced Sodium-Ion batteries.
The article provides insights into India’s API industry, highlighting its position in global markets with respect to production volume and value. It also includes the opportunities available and the challenges faced by manufacturers.
We are thrilled to announce the commencement of construction of our new Active Pharmaceutical Ingredient (API) manufacturing facility.
The article covers everything about what is API custom synthesis, considerations before undertaking API synthesis, steps involved in API custom synthesis, and physicochemical assessment of APIs.
Recent advances in cancer research have highlighted methylene blue as a promising compound for its therapeutic benefits in oncology. This article includes mechanism of action of methylene blue as anticancer agent to its clinical potential & future direction.
Ciclopirox Olamine is an antifungal agent used for the treatment of fungal infections of the skin and nails. This article includes a brief overview of its properties, mechanism of action, uses & side effects.
Pharmaceutical NIR dyes are used for in vivo imaging, visualization & other diagnostic applications. This articles includes information about their classification, applications and trial phase.
As we conclude another remarkable year at Macsen Labs, we review a period characterized by expansion and new initiatives. This retrospective review covers our organization's key accomplishments in 2023-24.